Slide 1: Second Quarter 2021 Results
K Pharm Second Quarter 2021 Results Trademarks referenced herein are held by their respective owners
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended Forward-looking st
Slide 3: Q2 2021 Results Call Participants
Q2 2021 Results Call Participants + Travis Mickle, Ph.D. - President & Chief Executive Officer + R. LaDuane Clifton, CPA - Chief Financial Officer, Secretary & Treasurer
Slide 4: KemPharm: Recent Highlights
KemPharm: Recent Highlights AZSTARYS™ Solid Financial Position - Commercial launch on July 21, 2021 - Cash on hand as of Jun 30, 2021 = $132.3M - Expect royalties and sales milestones in - Q2 2021 net income of $6.2M, or $0.18 per 2022 and beyond basic share - Royalty rates on U.S. net sales of high
Slide 5: AZSTARYS - U.S. Commercial Launch
ASTARYS™ - U.S. Commercial Launch v¥ On July 21, 2021, Corium, Inc. initiated U.S. commercial launch of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, Cll) Consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of d- methylphenidate (d-MPH), co-formulated with immediate-relea
Slide 6: AZSTARYS Commercialization Update
AZSTARYS™ Commercialization Update * AZSTARYS launched July 21%, 2021 + Initially a focused launchin a few states with select prescribers + Payor discussions ongoing o Typical game with all new products: Initial NCD blocks and resistance o Some payors have indicated initial receptivity to AZSTARYS a
Slide 7: Serdexmethylphenidate (SDX) Opportunity
Serdexmethylphenidate (SDX) Opportunity SDX provides an opportunity to explore indications outside ADHD o SDX is the only C-IV methylphenidate product; all others are C-Il o SDX has a unique pharmacokinetic profile allowing for gradual and continuous release throughout the day o No generic equivalen
Slide 8: Financial Update
Financial Update
Slide 9: Q2 2021 Financial Results
Q2 2021 Financial Results + Revenue of $12.0M, comprised of $10.0M milestone payment for DEA scheduling of SDX, and service fee revenue of $2.0M + Net income of $6.2M, or $0.18 per basic share, compared to net income of $0.9M, or $0.21 per basic share and diluted share for Q2 2020 o Operating income
Slide 10: Q2 2021 Balance Sheet Update
Q2 2021 Balance Sheet Update + As of June 31, 2021, total cash was $132.3M, an increase of $56.3M compared to Mar 31, 2021, primarily due to receipt of $20M in cash milestones related to AZSTARYS, and $40.6M in proceeds from warrant exercises during Q2 2021 + Completed warrant exercise inducement tr
Slide 11: Solid Financial Position
Solid Financial Position + KemPharm’s balance sheet has been completely restructured and recapitalized with a cash balance that provides for: o operating requirements, o internal development opportunities, and o other potential external investments + Shelf registration on Form S-3 is just another co
Slide 12: KemPharm: Looking Ahead
KemPharm: Looking Ahead AZSTARYS™ - U.S. commercial rollout is being led by Corium and is progressing as planned - KemPharm continues to support manufacturing, scientific and regulatory affairs - Expect royalties and sales milestones in 2022 and beyond | Improved Financial Position - Cash on hand as
Slide 13: Second Quarter 2021 Results
K Pharm Second Quarter 2021 Results